EAM Investors LLC Makes New $1.05 Million Investment in Pro-Dex, Inc. (NASDAQ:PDEX)

EAM Investors LLC bought a new position in shares of Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 22,399 shares of the medical instruments supplier's stock, valued at approximately $1,047,000. EAM Investors LLC owned approximately 0.69% of Pro-Dex as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC increased its position in shares of Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock worth $119,000 after purchasing an additional 1,028 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Pro-Dex during the 4th quarter valued at $202,000. Trexquant Investment LP bought a new stake in shares of Pro-Dex during the 4th quarter worth $252,000. Integrated Quantitative Investments LLC purchased a new position in Pro-Dex in the fourth quarter worth $254,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in Pro-Dex in the fourth quarter valued at $255,000. 15.28% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Raymond E. Cabillot sold 836 shares of Pro-Dex stock in a transaction on Monday, March 31st. The shares were sold at an average price of $50.00, for a total value of $41,800.00. Following the transaction, the director now directly owns 278,109 shares of the company's stock, valued at $13,905,450. The trade was a 0.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 28,699 shares of company stock worth $1,339,828 in the last ninety days. 47.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Separately, StockNews.com cut Pro-Dex from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th.

Pro-Dex Price Performance

Shares of PDEX stock traded up $2.11 during trading hours on Tuesday, hitting $60.42. 11,904 shares of the company's stock were exchanged, compared to its average volume of 24,854. Pro-Dex, Inc. has a 12-month low of $16.84 and a 12-month high of $65.87. The company has a market capitalization of $197.03 million, a PE ratio of 30.22 and a beta of 0.40. The business's 50 day simple moving average is $46.87 and its 200-day simple moving average is $43.65. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, equities research analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Pro-Dex Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.